Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
| Autor: | Dimitra Papadimitriou, Fotini Galapi, K Papadias, Irene Lambrinoudaki, Sophia A. Vlachou |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
myalgia
medicine.medical_specialty bisphosphonate medicine.medical_treatment Osteoporosis Urology Review Zoledronic Acid Drug Administration Schedule Bone remodeling postmenopausal osteoporosis Fractures Bone medicine Humans Infusions Intravenous Osteoporosis Postmenopausal Femoral neck Bone mineral Bone Density Conservation Agents Diphosphonates business.industry Imidazoles RC952-954.6 General Medicine Bisphosphonate medicine.disease Surgery Postmenopause Zoledronic acid medicine.anatomical_structure Treatment Outcome Geriatrics Female Geriatrics and Gerontology medicine.symptom business Osteonecrosis of the jaw medicine.drug |
| Zdroj: | Clinical Interventions in Aging, Vol Volume 3, Pp 445-451 (2008) Clinical Interventions in Aging Scopus-Elsevier |
| ISSN: | 1178-1998 |
| Popis: | Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, GreeceAbstract: Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that has recently been approved for the treatment of postmenopausal osteoporosis as an annual intravenous infusion. Zoledronic acid is an antiresorptive agent which has a high affinity for mineralized bone and especially for sites of high bone turnover. Zoledronic acid is excreted by the kidney without further metabolism. Zoledronic acid administered as a 5 mg intravenous infusion annually increases bone mineral density in the lumbar spine and femoral neck by 6.7% and 5.1% respectively and reduces the incidence of new vertebral and hip fractures by 70% and 41% respectively in postmenopausal women with osteoporosis. Most common side effects are post-dose fever, flu-like symptoms, myalgia, arthralgia, and headache which usually occur in the first 3 days after infusion and are self-limited. Rare adverse effects include renal dysfunction, hypocalcemia, atrial fibrillation, and osteonecrosis of the jaw.Keywords: zoledronic acid, postmenopausal osteoporosis, bisphosphonate |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|